Jubilant Pharmova Q2 FY27: revenue up 20.5% to ₹2,370 Cr, net profit down 74.1% to ₹31 Cr
Results · 16 Nov 2026 · Jubilant Pharmova (JUBLPHARMA)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 2,370 | +20.5% |
| Operating profit | 241 | -29.6% |
| Net profit | 31 | -74.1% |
In Q2 FY2027, revenue grew 21% year-on-year to Rs.2,370 Crores across all business segments, with EBITDA at Rs.255 Crores and profit after tax at Rs.31 Crores.
EBITDA margins declined year-on-year due to unavailability of high-margin SPECT radiopharma products, negligible third-party revenues, and remediation costs at the Montreal facility.
Management expects H2 revenue growth momentum to continue and margins to improve quarter-on-quarter to mid-teens on average as SPECT supplies from Montreal stabilize.
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.